ProQR Therapeutics N.V. (PRQR)
ProQR Therapeutics N.V. (PRQR) Stock Price, Analysis & Data
| Bid | 1.36 |
| Market Cap | 264.6M |
| Revenue (ttm) | 13.64M |
| Net Income (ttm) | -45.49M |
| Beta | 0.03 |
| EPS (ttm) | -0.5 |
| PE Ratio (ttm) | n/a |
| Forward PE | -2.76 |
| P/B (ttm) | 4.54 |
| P/S (ttm) | 19.40 |
| Earnings Date | Aug 13, 2026 |
| Ask | 2.41 |
| Volume | 382,144 |
| Avg. Volume (20D) | 1,006,277 |
| Open | 1.91 |
| Previous Close | 1.92 |
| Day's Range | 1.86 - 1.92 |
| 52-Week Range | 1.33 - 3.10 |
| Analyst | n/a |
| Price Target | 8.5 (352.13%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About PRQR
ProQR Therapeutics N.V., a clinical-stage biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company develops an RNA editing platform through its Axiomer RNA editing technology for genetic disorders with unmet needs. Its lead product candidate, AX-0810, targets na-taurocholate cotransporting polypeptide (NTCP) for the treatment of cholestatic diseases. The company also develops AX-2402, which targe...
Financial Performance
In 2025, ProQR Therapeutics's revenue was 15.91M, a decrease of -15.86% compared to the previous year's 18.91M. Earnings were -42.18M, an increase of 51.94%.
Financial StatementsAnalyst Forecast
According to 8 analyst ratings, the average rating for PRQR stock is "null". The 12-month stock price forecast is 8.5, which is upside of 352.13% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
